HomeArticlesImpacting NewsCelularity Inc NK Cell Therapy CYNK-001 Receives US FDA Fast Track Designation for AML Treatment
Impacting News
Premium

Celularity Inc NK Cell Therapy CYNK-001 Receives US FDA Fast Track Designation for AML Treatment

Celularity Inc Celularity Inc. ( CELU ) announced the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for its non-genetically modified cryopreserved human placental hemato...
P

Prohost Biotech

1 min read
12
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Comments (0)

Please sign in to join the discussion